Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accumulated Depreciation: 2019-2021

Historic Accumulated Depreciation for Nurix Therapeutics (NRIX) over the last 3 years, with Nov 2021 value amounting to $14.9 million.

  • Nurix Therapeutics' Accumulated Depreciation rose 28.51% to $18.1 million in Q3 2022 from the same period last year, while for Aug 2022 it was $18.1 million, marking a year-over-year increase of 28.51%. This contributed to the annual value of $14.9 million for FY2021, which is 12.87% up from last year.
  • As of FY2021, Nurix Therapeutics' Accumulated Depreciation stood at $14.9 million, which was up 12.87% from $13.2 million recorded in FY2020.
  • In the past 5 years, Nurix Therapeutics' Accumulated Depreciation registered a high of $14.9 million during FY2021, and its lowest value of $11.0 million during FY2019.
  • In the last 3 years, Nurix Therapeutics' Accumulated Depreciation had a median value of $13.2 million in 2020 and averaged $13.0 million.
  • Data for Nurix Therapeutics' Accumulated Depreciation shows a peak YoY increased of 19.81% (in 2020) over the last 5 years.
  • Over the past 3 years, Nurix Therapeutics' Accumulated Depreciation (Yearly) stood at $11.0 million in 2019, then rose by 19.81% to $13.2 million in 2020, then rose by 12.87% to $14.9 million in 2021.